Partial
Partially Aligned
Patient Risk:
Low
Summary
The AI-generated claims largely align with the Wegovy label for indications, mechanism, pharmacodynamics, common adverse effects, and key warnings. Several claims are correctly supported by the label, but there are notable omissions and some claims that are not supported or are mischaracterized (e.g., injections site necrosis, pancreatitis/pancreatic cancer monitoring guidance, and certain pancreatitis history contraindications). A few statements are partly supported (combined prevalence of nausea/vomiting) or require caution in interpretation.
Category Scores
Accurate Statements
Wegovy is a prescription medication used to treat obesity and aid in weight loss.
1 Indications and Usage
Wegovy is a semaglutide injection.
1 Indications and Usage; 12.1 Mechanism of Action; 2 Dosage and Administration
Wegovy works by suppressing appetite.
12.2 Pharmacodynamics
Wegovy slows gastric emptying.
12.2 Pharmacodynamics
Nausea is among the most common side effects of Wegovy.
6.1 Adverse Reactions in Adults with Obesity or Overweight for Weight Reduction
Vomiting is among the most common side effects of Wegovy.
6.1 Adverse Reactions in Adults with Obesity or Overweight for Weight Reduction
Diarrhea is a side effect of Wegovy.
6.1 Adverse Reactions in Adults with Obesity or Overweight for Weight Reduction
Abdominal pain is a side effect of Wegovy.
6.1 Adverse Reactions in Adults with Obesity or Overweight for Weight Reduction
Redness at the injection site is a possible side effect of Wegovy.
2.2; 6.1 Adverse Reactions
Swelling at the injection site is a possible side effect of Wegovy.
2.2; 6.1 Adverse Reactions
Itchiness at the injection site is a possible side effect of Wegovy.
2.2; 6.1 Adverse Reactions
Up to 23% of patients experience injection site redness, swelling, or itchiness.
2.2; 6.1 Adverse Reactions
Injection site reactions are usually mild and temporary.
2.2; 6.1 Adverse Reactions
There is an increased risk of thyroid C-cell tumors associated with GLP-1 receptor agonists, including Wegovy, in animal studies.
5 WARNINGS AND PRECAUTIONS; 5.1 WARNING: RISK OF THYROID C-CELL TUMORS
The clinical significance of this finding is still being investigated.
5 WARNINGS AND PRECAUTIONS; 5.1 WARNING: RISK OF THYROID C-CELL TUMORS
Wegovy may cause hypoglycemia (low blood sugar).
5 WARNINGS AND PRECAUTIONS; 5.4 Hypoglycemia
Wegovy may cause hypersensitivity reactions.
5 WARNINGS AND PRECAUTIONS; 5.7 Hypersensitivity Reactions
Wegovy has been linked to pancreatitis in rare cases.
5 WARNINGS AND PRECAUTIONS; 5.2 Acute Pancreatitis
The association between Wegovy and pancreatitis is still being studied.
5 WARNINGS AND PRECAUTIONS; 5.2 Acute Pancreatitis
Patients taking Wegovy should monitor for signs of hypoglycemia.
5 WARNINGS AND PRECAUTIONS; 5.4 Hypoglycemia
Wegovy is not suitable for individuals with a history of pancreatitis.
4 CONTRAINDICATIONS
Patients with a personal or family history of thyroid cancer should consult their doctor before starting Wegovy.
4 CONTRAINDICATIONS; 5.1 WARNING: RISK OF THYROID C-CELL TUMORS
Unsupported Statements
Diarrhea is experienced by up to 35% of users.
Label provides specific adverse reaction percentages but does not state a 35% prevalence across users.
In rare instances, diarrhea may be severe and warrant medical intervention.
Label includes severe GI adverse reactions in 5.6 but does not explicitly tie severe diarrhea to that claim.
In rare instances, abdominal pain may be severe and warrant medical intervention.
Label does not explicitly state severe abdominal pain requiring intervention in rare instances.
Wegovy injection necrosis.
Not described anywhere in the label as an adverse effect.
Monitor for signs of pancreatic cancer.
Label discusses pancreatitis risk but does not recommend monitoring for pancreatic cancer.
Consult their doctor before starting Wegovy if there is a personal or family history of thyroid cancer.
Label discusses counseling about thyroid cancer risk and contraindication for personal/family history of MTC/MEN2, but does not include a general "consult doctor before starting" directive for thyroid cancer history beyond contraindication and warning content.
Contradictions
Low
AI Statement
Diarrhea is experienced by up to 35% of users.
Label Reference
6.1 Adverse Reactions
Important Omissions
Explicit guidance to monitor for pancreatic cancer is not provided in the label.
Importance:
Moderate
Pancreatitis history as a contraindication is not listed (pancreatitis history is not a labeled contraindication).
Importance:
Moderate
Official guidance to consult a clinician before starting Wegovy for thyroid cancer risk history is not stated beyond contraindication and counseling language.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Risks described in the label (GI events, hypoglycemia with other agents, thyroid tumor risk in animals, pancreatitis) are acknowledged; no new, unlabelled safety concerns are asserted.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Partially Aligned
Primary Issue
Misplaced or unsupported claims (e.g., injection site necrosis; pancreatic cancer monitoring; pancreatitis history contraindication) and an overextended diarrhea prevalence claim.
Suggested Improvement
Restrict assertions to label-supported statements; remove claims not present in the label; correct prevalence figures to reflect label data; avoid recommending monitoring for pancreatic cancer unless explicitly stated; remove contraindication for pancreatitis history unless supported by label.